Crescent Biopharma Lays Out CR-001/CR-002/CR-003 Data Calendar; APOLLO Starts Q4 2026
CBIO sits 43% above its 52-week low of $8.72.
Summary
Crescent Biopharma disclosed a full clinical timeline: CR-001 combination cohorts now enrolling with data from Q1 2027, CR-002's APOLLO Phase 1/2 starting Q4 2026, and CR-003 proof-of-concept data expected Q1 2027.
Key Events · Product Development and Regulatory · CBIO
-
ASCEND Combination Cohorts Enrolling
CR-001 plus standard-of-care chemotherapy expansion cohorts are enrolling across seven tumor types/regimens, including 1L NSCLC, 1L pMMR/MSS CRC, 3L CRC, 1L biliary tract, 1L pMMR endometrial and 1L/2L PD-L1+ gastric/GEJ cancer.
-
Monotherapy Data Due Q1 2027
ASCEND monotherapy dose escalation is complete; initial data will include ORR from up to 12 first-line NSCLC patients plus safety, PK and PD data from more than 125 patients across solid tumors.
-
CR-002 APOLLO Trial Starts Q4 2026
Following the October 5, 2026 FDA IND allowance, the global Phase 1/2 APOLLO trial of PD-L1-targeted ADC CR-002 is on track to begin in Q4 2026, with initial data expected in H2 2027.
-
Kelun-Biotech ADC Combinations Advance
Two Phase 2 trials of CR-001 (SKB118) plus sac-TMT are ongoing, a third is initiating in EGFR-mutant NSCLC, and a Phase 1/2 of CR-001 plus CR-003 (SKB105) is expected to start in H1 2027.
Analysis · CBIO · Life Sciences
Crescent used an 8-K to publish a detailed clinical execution roadmap across its three assets. CR-001's global Phase 1/2 ASCEND trial has finished monotherapy dose escalation and begun enrolling standard-of-care chemotherapy combination cohorts in seven tumor settings, with initial monotherapy data due Q1 2027 and combination data mid-2027; the first of several Phase 3 trials is planned for early 2028. CR-002, cleared by the FDA on October 5, 2026, is on track to start the Phase 1/2 APOLLO trial in Q4 2026 with data in H2 2027, and partner Kelun-Biotech is running multiple combination studies in China with CR-003 proof-of-concept data expected Q1 2027. For a clinical-stage company, the value of this filing is the schedule itself: it converts a broad pipeline story into dated milestones investors can track, and it confirms the July offering proceeds are being deployed into trials rather than sitting idle. The risk is that every one of these dates is a forward-looking target — the filing carries no efficacy or safety results, so nothing here de-risks the programs today.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 32.5% of the 1969 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CBIO was trading at $12.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $463.6M. The 52-week trading range was $8.72 to $27.41. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.